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Stroke in the neonatal brain frequently results in neurologic impairments including cognitive
disability. We investigated the effect of long-term sodium valproate (valproate) and
trichostatin A (TSA) treatment upon post-stroke neurogenesis in the dentate gyrus (DG)
of stroke-injured immature mice. Decreased or abnormal integration of newborn DG
neurons into hippocampal circuits can result in impaired visual-spatial function, abnormal
modulation of mood-related behaviors, and the development of post-stroke epilepsy.
Unilateral carotid ligation of P12 CD1 mice was followed by treatment with valproate,
TSA, or vehicle for 2 weeks, bromodeoxyuridine (BrdU) administration for measurement
of neurogenesis, and perfusion at P42 or P60. Behavior testing was conducted from P38–
42. No detrimental effects on behavior testing were noted with TSA treatment, but mildly
impaired cognitive function was noted with valproate-treated injured animals compared
to normal animals. Signiﬁcant increases in DG neurogenesis with both TSA and valproate
treatment were noted with later administration of BrdU. Increased mortality and impaired
weight gain was noted in the valproate-treated ligated animals, but not in the TSA-treated
animals. In summary, the impact of histone deacetylase (HDAC) inhibition upon post-stroke
subgranular zone neurogenesis is likely to depend on the age of the animal at the time point
when neurogenesis is assessed, duration of HDAC inhibition before BrdU labeling, and/or
the stage in the evolution of the injury.
Keywords: valproate, trichostatin A, neonatal stroke, hippocampal neurogenesis, behavioral outcomes, anticon-
vulsants, histone deacetylase inhibitors
INTRODUCTION
Neonatal stroke commonly results in cognitive impairments and
other neurologic consequences in approximately 75%of survivors.
While the extent of functional recovery after neonatal stroke can
be remarkable due to the ongoing neuroplasticity and brain devel-
opment, nevertheless the lifetime consequences of the neonatal
stroke remain signiﬁcant. A fundamental question of interest is
how the enhanced neuroplasticity of the immature brain can best
be harnessed to improve long-term outcomes. One class of drugs
with potential to positively inﬂuence post-stroke neurogenesis and
regeneration is histone deacetylase (HDAC) inhibitors. Recent
studies have provided signiﬁcant evidence of neuroprotection by
HDAC inhibitors after stroke in the mature brain associated with
HDAC4 acetylation (Liu et al., 2012), increased angiogenesis via
up-regulation of Hif-1α (Wang et al., 2012), decreased inﬂamma-
tory markers and activated microglia, HSP70 induction, increased
Abbreviations: BrdU, bromodeoxyuridine; DG, dentate gyrus; GCL, granule cell
layer; HDAC, histone deacetylase; SGZ, subgranular zone; TSA, trichostatin A;
VPA/valproate, sodium valproate.
phospho-Akt, and decreased pro-apoptotic proteins such as p53
(Kim et al., 2007). The few available studies suggest evidence of
neuroprotection in the immature brain as well (Kabakus et al.,
2005; Sandner et al., 2011; Fleiss et al., 2012). Studies addressing
the impact of HDAC inhibitors upon post-stroke neurogenesis
remain extremely limited (Kim et al., 2009; Liu et al., 2012), how-
ever, particularly in the immature brain. Many aspects of the
evolving post-stroke injury and regenerative response differ in the
immature brain from that in the mature brain, and therefore stud-
ies should be done in clinically relevant animal models of neonatal
stroke.
Histone deacetylases, of which there are currently 11 in 5 differ-
ent sub-groups, are enzymes involved in the epigenetic regulation
of gene expression and protein function, and are partly responsi-
ble for the control of long-term changes in neuronal functions.
Histone acetyltransferase (HAT) facilitates histone acetylation,
releases condensed chromatin, and increases gene transcrip-
tion (Bannister and Kouzarides, 2011). HDACs, on the other
hand, remove acetyl groups from histone, thereby promoting
chromatin condensation and repression of gene transcription.
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HDAC inhibitors can, however, also decrease activation of some
genes by increasing gene repressor transcription. Furthermore,
non-histone proteins important in microtubule stability have also
been shown to serve as substrates for certain HDACs (Zhang
et al., 2003), demonstrating the importance of acetylation in
post-translational protein regulation. Therefore their effects are
expected to be complex and dependent upon the developmental
and contextual milieu. Valproate has been shown to affect gene
expression in millimolar concentrations through its direct action
as an inhibitor of primarily class 1 HDACs (Gottlicher et al., 2001;
Phiel et al., 2001), and to a lesser extent class 2, but not HDAC6
or HDAC10 (Gurvich et al., 2004) The hydroxamic acid tricho-
statin A ([R-(E,E)]-7-[4-(dimethylamino) phenyl]-N-hydroxy-
4,6-dimethyl-7-oxo-2,4-heptadienamide; TSA) is a potent HDAC
inhibitor, structurally dissimilar to valproate, demonstrated to
inhibit class 1 and class 2 HDACs in nanomolar amounts (Yoshida
and Horinouchi, 1999).
Both valproate and TSA have been shown to suppress cell
growth by cell cycle arrest and promotion of cell differentia-
tion (Drummond et al., 2005). This proﬁle has led to their wide
study in the setting of cancer. Effects of valproate on the stim-
ulation of neurogenesis and neurotrophic pathways have also
been reported. Valproate has been shown to promote neural dif-
ferentiation via the increased expression of the proneural genes
Ngn1, Math1, and P15 associated with the increased acetylation
of H4 (Yu et al., 2009). Increased neurogenesis after ischemia
in a rat model treated with sodium butyrate was associated
with increased expression of BDNF and phospho-Creb (Kim
et al., 2009). Developmental differences have been noted in the
role of HDACs in neurogenesis. For example, there is evi-
dence that HDAC2 is critical for adult neurogenesis, but not
required for embryonic neurogenesis (Jawerka et al., 2010); there-
fore HDAC inhibitor selectivity is important as is the context of
its use.
Recent studies suggest that HDAC inhibitors are also effective
for treating neurodegenerative disorders or enhancing synap-
tic plasticity (Hockly et al., 2003; Vecsey et al., 2007). Disrupted
cellular acetylation homeostasis of histones and other proteins
has been shown to be a common feature in neuropathological
states, including stroke (Chuang et al., 2009; Selvi et al., 2010).
Neurodegeneration is associated with decreased HAT activity,
resulting in relative over-deacetylation. HDAC inhibitors have
therefore been tested for therapeutic efﬁcacy with promising
results in models of stroke, Huntington disease, amyotrophic
lateral sclerosis and experimental autoimmune encephalomyeli-
tis. Similarly, the number of acetylated histone (AH3) positive
cells was decreased by cerebral ischemia in a stroke model and
restored by HDAC inhibitor treatment in the ipsilateral dentate
gyrus (DG) 14 days after the stroke injury. Most AH3 (+) cells
were found to co-localize with neuronal nuclei (NeuN) marker
indicating an association of HDAC inhibition with the increased
neurogenesis (Kim et al., 2009). Very little is known about the
effect of HDAC inhibitors in the immature brain, however, with or
without an overriding developmental insult such as stroke. While
valproate is not considered an anticonvulsant of choice for infants,
because of the risk of liver failure, nevertheless studying its effects
as an anticonvulsant with HDAC inhibitory effects may serve
as a proof of principle from which to derive novel regenerative
approaches.
Neurogenesis has been shown to occur in the brain at a high
rate during embryonic and early postnatal development and to
persist at a slower rate for the remainder of life. Although post-
natal neurogenesis has been reported to exist in many brain areas,
it is seen most consistently in two: the DG of the hippocampus
and the subventricular zone of the lateral ventricles. The hip-
pocampus has long been implicated in memory recall, learning,
emotion, and cognition; with ablations or lesions usually leading
to deﬁcits in associated tasks (Scoville and Milner, 1957; Kim et al.,
2012). In the DG, cells added later in life are similar in connectivity
and ﬁring pattern as those born during embryonic development
(Laplagne et al., 2007). Studies have been conducted showing
immediate early gene upregulation in newborn neurons following
novel exploration experiences (Kadam et al., 2010). Together, this
indicates that these newborn cells have the capability of function-
ally integrating with existing circuits. The precise effect of altered
levels of neurogenesis on cognitive performance remains an active
subject of research.
The unilateral carotid ligation model used here with double lig-
ation of the right common carotid ligation, is a modiﬁcation of the
original carotid ligation model (Comi et al., 2004), and produces
a range of injury to the cortex, hippocampus, thalamus and stria-
tumas described in this initialmanuscript.We have found that this
type of insult produces stroke and injury with more than 70% of
the ligated P12 CD1 mice (Comi et al., 2004). The double carotid
ligation is done to ensure ligation of the vessel but does not alter
the extent of the injury. The carotid ligation P12 mouse model of
stroke in the immature brain has been associated with decreased
subgranular zone (SGZ) proliferation and neurogenesis (Kadam
et al., 2008, 2009a) and impairments in cognitive function related
to hippocampal function (Kadam et al., 2009b). One advantage
of the P12 mouse carotid ligation model is that it induces acute
behavioral seizures; this feature mimics the presentation of neona-
tal stroke with seizures in human infants and, because the severity
of the acute seizures correlates with the severity of the brain injury,
we use this feature to distribute the injured animals between the
drug and vehicle treatment groups.
The goal of this study was to determine the long-term effects
of an anticonvulsant known to be an HDAC inhibitor, and that
of a potent HDAC inhibitor with no known anticonvulsant action
(Hoffmann et al., 2008), on post-stroke neurogenesis and behav-
ioral outcome. We therefore tested valproate and TSA in a CD1
mouse model of stroke in the immature brain. We hypoth-
esized that both HDAC inhibitors would promote post-stroke
neurogenesis in the immature brain.
MATERIALS AND METHODS
All materials and methods were approved by the Johns Hopkins
University Animal Care and Use Committee. Litters of CD1 mice
were purchased from Charles River Laboratories Inc. (Wilming-
ton, MA, USA). Pups were housed in polycarbonate cages with
the dam on a 12-h light:dark cycle; food was provided ad libi-
tum. Pups from 13 litters used for Protocol 1 (see Table 1 for
details) were randomly assigned to one of the four treatment
groups [i.e., 200 mg/kg valproate twice a day, a dose selected as
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Table 1 | Numbers of ligated mice for each set of experiments.
Valproate Saline TSA DMSO
Groups for Protocol 1
Assigned to each group, n 28 21 19 16
Mortality during treatment, n 5 2 3 2
Mortality after treatment, n 3 0 2 1
Surviving to perfusion, n 20 19 14 13
Stroke-injured at P60, n (%) 15 (75.0),
1 microinjured
15 (78.9),
4 microinjured
9 (64.3),
1 microinjured
10 (76.9)
Injured, n 15 (7 male) 15 (6 male) 9 (4 male) 10 (5 male)
Uninjured, n 5 (4 male) 4 (4 male) 5 (3 male) 3 (1 male)
Groups for Protocol 2
Assigned to each group, n 21 20 16 10
Mortality during treatment, n 4 2 1 1
Mortality after treatment, n 2 0 0 0
Surviving to perfusion, n 15 18 15 9
Stroke-injured at P42, n (%) 8 (53.3) 9 (50.0) 10 (66.7) 4 (44.4)
Injured, n 8 (5 male) 9 (3 male) 10 (3 male) 4 (3 male)
Uninjured, n 7 (1 male) 9 (7 male) 5 (3 male) 5 (1 male)
both anticonvulsant in rodents and effective as an HDAC inhibitor
(Hoffmann et al., 2008), saline, 2.5 mg/kg TSA twice a day, or 5%
DMSO] beginning 4 days after ligation. For Protocol 2, a total of
three litters of animals were used for testing TSA versus 5% DMSO
control, ﬁve litterswereused for testing valproate versus saline con-
trol, and pupswere randomly assigned to receive drug versus saline
control except that animals with seizures were evenly distributed
between the two treatment groups (see Table 1 for details). For
details of Protocols 1 and 2, see schematic in Figure 1). An addi-
tional two litters of pups were administered valproate for serum
analysis of drug levels. Researchers were blinded to the treatment
groups for all analyses reported here.
ISCHEMIC STROKE AT P12
Newly born litters of pups arrived at postnatal 5 days old and were
allowed to acclimate for 7 days. On P12, animals were subjected to
permanent unilateral double ligation of the carotid artery, adapted
from previous studies (Comi et al., 2004). In brief, animals were
anesthetized with isoﬂurane carried by a 50–50 mixture of O2 and
NO. The right common carotid artery was double ligated with 6-0
surgisilk and the outer skin closed with 6-0 monoﬁlament nylon.
Sham control animals were treated identically except the carotid
was neither dissected nor ligated.
ACUTE SEIZURE SCORING
Seizure activity was scored according to a seizure rating scale
as previously reported. Immediately following ligation or sham
surgery, pups were kept in an incubator at 36.5–37◦C for 4 h dur-
ing which seizure activity was monitored (Kadam et al., 2010).
After 4 h, the mice were returned to the dam and each of their
seizure scores was individually summed to produce a total acute
seizure score. In these experiments, since seizure severity has been
repeatedly shown to correlate with severity of brain injury in this
model, seizure scores were used to help distribute injured animals
as evenly as possible between the treatment groups. Mice with
similar seizure score severities were randomly assigned to each
treatment group.
ANTICONVULSANT TREATMENT
Drug or vehicle was administered twice daily at 9 am and 5 pm
by intraperitoneal injections for 2 weeks, and then weaned off
over 2 days (see schematic in Figure 1). Valproic acid sodium
salt (Cat # P4543, Sigma, St. Louis, MO, USA) was dissolved in
sterile water for injections in working solution concentrations of
100 mg/ml and injected at 200 mg/kg. Saline was injected as the
vehicle control for valproate. TSA (Cat# met-tsa-5, Invitrogen)
was reconstituted in a 5% DMSO solution in a concentration of
0.5 mg/ml and injected at 2.5 mg/kg. 5% DMSO (in saline) was
injected as the vehicle control for TSA.
SERUM COLLECTION AND ANALYSIS
Serum was collected for analysis of valproate concentration. Two
litters (n = 20 mice; 3 died before collection of blood) received
intraperitoneal injections of valproate twice daily, along the same
time-scale as other mice, although without ligations or any
bromodeoxyuridine (BrdU) injections. On P26, animals were
assigned to have blood collected during either a time-point before
the morning injections (to represent trough levels), an hour after
morning injections (to represent peak levels), before evening injec-
tions (trough levels), or an hour after evening injections (peak
levels). Mice were exposed to CO2 for 2 min or until breathing
ceased. The ribcage was then opened and the heart exposed. Blood
was collected by syringe via a cardiac puncture. It was left to sit at
room temperature for an hour, and then put in a centrifuge at 4◦C
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FIGURE 1 | Schematics of Protocols 1 and 2. (A) Schematic for Protocol 1. Cognitive testing was done with these animals. (B) Schematic for Protocol 2.
These mice received BrdU later and were euthanized sooner than in Protocol 1. These mice did not have cognitive testing done.
to spin for 15min at 14000 g. The serumwas then aspirated off and
sent to the Auburn University Clinical Pharmacology laboratory
for analysis of drug concentration.
BROMODEOXYURIDINE LABELING AND TISSUE PREPARATION
Bromodeoxyuridine (BrdU; Sigma) reconstituted in 0.9% NaCl
was intraperitoneally injected (ﬁve injections; 50 mg/kg) at
P20–22 in Protocol 1 and P24–26 in Protocol 2. All the mice
in the study were anesthetized with chloral hydrate (90 mg/ml;
intraperitoneally) before being transcardially perfused with PBS
followed by phosphate buffered 10% formalin, then having brains
removed and post-ﬁxed in the same ﬁxative for 5 days. The brains
were cryoprotected in sucrose after which they were rapidly frozen
using dry ice and placed in −80◦C storage. Coronal brain sections
40μmthickwere cut on a cryostat in serial order to create six series
of sections that were mounted on super frost plus glass slides and
stored at −20◦C.
COMPUTERIZED BRAIN ASYMMETRY ANALYSIS
Using MCID 7.0 Elite (InterFocus Imaging Ltd, Cambridge, UK)
brain atrophy scores (of the affected right side compared to the
contralateral side) were measured for evenly spaced Nissl stained
brain sections spanning between the levels of the anterior horn
of the lateral ventricle and the caudal hippocampus as previ-
ously described. For each brain, hippocampal, and hemispherical
atrophy scores from a series of equidistant sections were com-
bined to calculate average atrophy scores as previously described
(Markowitz et al., 2011).
IMMUNOHISTOCHEMISTRY
The following primary antibodies were used: mouse anti-BrdU
(1:200, BMC9318, Roche Applied Sciences, Indianapolis, IN,
USA), mouse anti-NeuN (1:2000, MAB377 Chemicon, Temec-
ula, CA, USA), rabbit anti-NeuN (1:1000, ABN78, Chemicon).
Antigen retrieval was performed with citrate buffer (pH 6.0),
and then DNA denaturated with HCL (2 mol/l), after which
slides were neutralized with 0.1 M borate buffer (pH 8.5). After
blocking non-speciﬁc binding sites, primary antibodies were
applied. Anti-BrdU and anti-NeuN were then linked to Alexa
Fluors 488 and 594 (1:400, Invitrogen), respectively.
NEUROGENESIS ASSESSMENT
Counts were performed with an Olympus BX61 microscope
equipped with ﬁlter cubes for visualizing ﬂuorophores absorb-
ing in blue, green, and red ranges. SGZ was deﬁned as the two-cell
thick layer between theGCL andhilus. Cells on the border between
SGZ and GCL were included in SGZ counts if greater or equal to
half of the cell was within the SGZ area. Cell counts were done
in ﬁve consecutive sections per brain series (coordinates of which
ranged roughly from Bregma −1.46 to −2.70 mm; Paxinos and
Franklin, 2001) and average cell densities calculated for each area
bilaterally. Thus 100% sampling (i.e., shown to be equivalent to
a sampling grid of counting frames adjacent to one another cov-
ering the entire regions of interest, ROI; Crews et al., 2004) was
done through entire ROIs in the maximum number serial coronal
sections (n = 5) in which the ROIs could be clearly deﬁned in
the ipsilateral injured hemisphere (Manaye et al., 2007) by closed
contours. This method, a modiﬁcation of systematic random sam-
pling was done as described previously by Manaye et al. (2007),
where every cell of interest (i.e., BrdU positive cell) in the ROIs
was counted. We started from section at which both DG blades are
formed and included all cells that expressed BrdU. Our method
allowed for cycling through the z-axis, live visualization under a
ﬁlter that showed green and red channels simultaneously (for co-
labeling which was conﬁrmed by images obtained with an Zeiss
Imager. M2 with an ApoTome attachment, see Figure 2), as well as
live visualization in single channels in order to ascertain whether
labeling was within the same cell or labeling of overlapping cells.
Density of newly born cells in the GCL was determined by divid-
ing the number of BrdU-labeled cells co-labeled with NeuN, by
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FIGURE 2 | ApoTome image of localization of BrdU and NeuN within DG. (A) Representative image of a cell within SGZ that is BrdU+ and expressed NeuN
as well. (B) Representative image of a cell within SGZ that is BrdU+ but does not express NeuN.
the area of the GCL as measured by MCID. Density of newly born
neural cells in the SGZ was determined by dividing the number
of BrdU-labeled cells co-labeled with NeuN, by the length of the
SGZasmeasuredbyMCID.Counts of cells in theGCLwere unique
and non-inclusive of the cells seen in the SGZ.Additionally, counts
were obtained for the hilus, deﬁned as the area between the two
blades of the granule cell layer, excluding cells in the SGZ. Per-
centages for co-labeling for GCL and SGZ were determined by
the following formula: [(BrdU+NeuN+ cell density)/(BrdU+ cell
density)] × 100.
BEHAVIORAL TESTING
Open ﬁeld test
Apparatus. Open ﬁeld assessments were carried out in square
ﬁelds (40.6 cm× 40.6 cm,Accuscan,Columbus,OH,USA) that are
mounted within specially designed sound attenuating chambers
constructed of polypropylene and polyvinyl chloride (PVC). The
ﬁelds were illuminated only by dim red light (6 V). Behavior was
monitored via a grid of invisible infrared light beams mounted on
the sides of the walls of the arena and equally spaced from the front
to back and from left to right. Data was collected and analyzed via
VersaMax Analyzer software (Accuscan, Columbus, OH, USA),
which is capable of determining the position of a mouse 50 times
per second.
Procedure. Toexamine activity levels andhabituation,micewere
exposed to the test chambers for 30min on each of two consecutive
days. To begin a session, each mouse was placed in the center of the
chamber and allowed to move about freely. The arena was cleaned
with 70% ethanol after each mouse completed a session.
T-MAZE SPONTANEOUS ALTERNATION
Apparatus
This procedure was carried out in an enclosed “T” shaped maze
(Med Associated, St. Albans, VT, USA) in which the long arm of
the T (47 cm × 10 cm) serves as a start arm and the short arms of
the T (35 cm × 10 cm) serve as the goal arms.
Procedure
In this task the mouse was placed in the start arm and after 5 s
the door was opened and the mouse was allowed to choose and
explore one of the goal arms. When the mouse had fully entered
the choice arm (tail tip all the way in) the arm was closed and
the mouse was conﬁned to the choice arm for 30 s. The mouse
was then removed, the guillotine door lifted and the next trial
initiated. This was repeated for a total of 15 trials. If the mouse did
not make a choice within 2 min the trial was ended and advanced
to the next. At the conclusion of each trial the maze was cleaned
with 70% ethanol to eliminate odors.
NOVEL OBJECT PREFERENCE
Apparatus
Novel object preference assessment is carried out in the same
chambers as the open ﬁeld above.
Procedure
The novel object preference was carried out over 2 days
immediately following the open ﬁeld test described above. On
day 1 of the preference test mice were placed in the open ﬁeld
described above and allowed to move about freely for 30 min.
As this session follows the prior two sessions in the open ﬁeld,
the additional session during the preference test serves to further
habituate the mice to the chambers and ensure that the cham-
ber environment is no longer novel. On day 2 of the preference
test, mice were again placed in the chambers and exposed to
various objects (plastic strawberry, miniature ﬂower pot, metal
star, or small stone) to assess novel object preferences. This
took place in two stages, a sample phase and a test phase. Dur-
ing the sample phase, two identical objects were mounted to
the ﬂoor of the open ﬁeld on opposite sides of the arena and
equidistant from the walls. Mice were placed into the center of
the open-ﬁeld, and allowed 10-min to explore. At the end of
the sample phase, each mouse was returned to the home cage
for a 3-min interphase interval (IPI) during which one of the
objects was replaced with a different object. Following the IPI,
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mice were returned to the ﬁeld and given a 10-min test phase.
The time each mouse spent exploring each object during each
phase was recorded and this measure serves as an index of object
preference.
METHODS OF ANALYSIS
Statistical analyses were run in SPSS for Windows (SPSS Inc.,
Chicago, IL, USA) and SYSTAT 12 (SYSTAT software, Inc.,
Chicago, IL,USA).ANOVAswere carried out to analyze behavioral
data and weight data. Independent sample T tests were carried out
to analyze the area and count data for the ipsilateral and con-
tralateral sides in the ligation-injured group comparing treatment
groups. Poisson regression was performed in rostral to caudal
analysis of neurogenesis data by section to determine the overall
signiﬁcance of treatment effects. Gender differences were noted
where relevant. A probability below 0.05 was considered signiﬁ-
cant. All mean values are presented ± standard error of the means.
Fisher’s exact tests were done to assess mortality and data from
mice that died were excluded from all other analyses.
To examine overall locomotor activity and habituation, mice
were observed in an open-ﬁeld over 2 consecutive daily sessions.
Analysis of all between session open ﬁeld data was performed on
only the ﬁrst half of each session (ﬁrst 15 min) because all of the
mice were the most active during this period and activity declined
substantially by the second half. Total distance traveled and rear-
ing activity served as indices of overall activity. Open ﬁeld data
was analyzed by ANOVAs in which the between session open ﬁeld
data were distance traveled and rearing, where Condition (Val-
proate, Saline, and Sham, or TSA,DMSO, and Sham) served as the
between subjects factor, and were day (day 1 session versus day 2
session) served as the within subjects factor. Analysis of within ses-
sion open ﬁeld measures included Condition as a between subjects
factor andTimeBlock (5min blocks of time) as thewithin subjects
factor. Analysis of rotational movements in the open ﬁeld included
Condition as a between subjects factor and rotation (clockwise
and counter-clockwise movements for day 1 session only) as the
within subjects factors. Spontaneous alternation on the T-maze
and the novel object preference data were analyzed with inde-
pendent sample t-tests. There were no performance differences
between male and females on any of the behavioral tests, thus
analysis was carried out collapsed across gender. A total of ﬁve
ligation-injured mice (two TSA, one DMSO, one Valproate, and
one saline) were excluded from analysis of the open ﬁeld data as
extreme outliers due to a fourfold increase in locomotion, and a
predominant clockwise wild running behavior demonstrated by
the mice on one or both days of testing. This abnormal behavior
has been previously described in this model (Kadam et al., 2010),
and is associated with severe brain injury and the development of
chronic behavioral seizures.
Of the mice that were ligated, only those that showed injury
were included in the analyses reported here (see Table 1). In all
cases where the injury was not obvious, microscopic examination
of cresyl violet-stained sectionswas done looking for focal atrophy,
gliosis, and cell loss. The few micro-injured brains (see Table 1)
were excluded from neurogenesis and behavioral analyses because
our prior studies have shown that this very mild form of injury
impact neurogenesis differently than themore severe stroke injury.
RESULTS
VALPROATE TREATMENT
Seizure scores
In Protocol 1, seizure scores in injured animals ranged from 0 to
41 (median = 0) in the valproate-treated and 0 to 66 (median = 0)
in the saline-treated animals (N.S.). In Protocol 2, seizure scores
ranged from0 to47 (median=12) in the valproate-treated and0 to
120 (median = 2) in the saline-treated (N.S.). Seizures correlated
with hemispheric brain atrophy in both valproate (r2 = 0.566,
p = 0.006) and saline treated animals (r2 = 0.463, p = 0.040).
Treatment groups and associated mortality
The sample size of valproate or saline treated ligated mice in Pro-
tocol 1 was n = 28 valproate- and 21 saline-treated (see Table 1
for details). Compared to saline (2/21 died), mortality associ-
ated with the valproate treatment (8/28 died) is not signiﬁcantly
higher (Fisher’s exact p = 0.16). The sample size for Protocol 2
is 21 ligated valproate- and 20 saline-treated ligated mice. Com-
pared to saline (2/20 died), mortality associated with the valproate
treatment (6/21 died) is higher but not signiﬁcantly so (Fisher’s
exact, p = 0.24). When the mortality data from the ﬁrst 42 days of
both protocols are added together, the mortality in the valproate-
treated group is signiﬁcantly higher compared to saline-treated
ligated animals (Fisher’s exact, p = 0.035).
Impact upon weight gain
Stroke-injured mice treated with valproate had lower weights
compared to saline-treated injured mice in both females and
males (Figure 3A; repeated measures ANOVA, p = 0.037).
This difference in weight occurred in both Protocols 1 and
2 and resolved after discontinuing the valproate treatment
(weight at P60 in valproate-treated = 27.9 ± 1.7 g and in
saline-treated = 29.0 ± 1.7 g, N.S., Protocol 1 and weight
at P42 in valproate-treated = 24.8 ± 1.8 g and in saline-
treated = 23.8 ± 1.3 g, N.S., Protocol 2).
Impact on brain atrophy
In Protocol 1 compared to its vehicle control group, in the
valproate-treated group of ligation-injured mice there was no
signiﬁcant change in stroke-injury atrophy at P60 (valproate:
32.5 ± 5.0% hemispheric and 53.2 ± 5.9% hippocampal atro-
phy versus saline: 25.5 ± 4.8% hemispheric and 50.3 ± 6.3%
hippocampal; p = 0.335 and 0.734, respectively). Similarly at P42
(Protocol 2), there were no signiﬁcant differences in brain atrophy
(see Figure 4A). No sex related differences within each group were
found to be signiﬁcant for severity of brain atrophy at P42 or at
P60.
Impact on neurogenesis
Comparing the neurogenesis in the GCL, SGZ and hilus, as
measured above, in both valproate- and vehicle-treated sham
surgery mice, to that in the contralateral DG of uninjured lig-
ated mice, there were no signiﬁcant differences (Protocol 1, data
not shown). Since neither valproate nor vehicle treated sham
surgery animals were signiﬁcantly different in their neurogene-
sis from the uninjured ligated animals, uninjured ligated animals
were used as controls for the neurogenesis studies; this pre-
vented the use of additional animals in Protocol 2. Protocol 1
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FIGURE 3 |Weight gain starting on the day of commencement of
treatment (P16) until cessation of treatment (P28) in ligation-uninjured
and ligation-injured mice (A) treated with valproate or saline-vehicle
(Protocol 2) or (B)TSA or DMSO-vehicle (Protocol 2; *p < 0.05,
**p < 0.01, ***p < 0.001).
treatment with valproate starting at P16 (i.e., 4 days after stroke-
insult) and BrdU labeling of proliferating cells at P20–22 (i.e.,
after 4–6 days of valproate exposure) did not show any signif-
icant effect on DG neurogenesis in the dorsal hippocampus in
stroke-uninjured mice (mean density of BrdU labeled cells in
contralateral GCL + SGZ in valproate = 813 ± 208 cells/mm2
versus saline = 533 ± 66 cells/mm2, p = 0.259; mean
ipsilateral density in valproate = 828 ± 205 cells/mm2 ver-
sus saline = 520 ± 73 cells/mm2, p = 0.241) or in
the stroke-injured mice (mean contralateral density in val-
proate = 621 ± 58 cells/mm2 versus saline = 605 ± 40,
p = 0.829 cells/mm2; mean ipsilateral density in val-
proate= 620± 129 cells/mm2 versus saline= 448± 52 cells/mm2,
p = 0.303).
However, with administration of the BrdU later, from P24–P26,
and assessing BrdU–NeuN co-labeling at P42, increased density of
co-labeled cells was noted when comparing valproate-treated mice
to saline-treated counterparts. Valproate-treated injured GCL new
cell density was signiﬁcantly increased relative to controls ipsilater-
ally (p = 0.046) and a trend was noted for increase contralaterally
(p = 0.074; see Figure 4B). Valproate similarly signiﬁcantly
increased new cell densities in ligation-uninjured mice in ipsilat-
eral and contralateral GCL (p = 0.027 and 0.016, respectively; see
Figure 4B). Therewere no signiﬁcant differences in percent of cells
labeled with BrdU expressing NeuN within GCL, when compar-
ing valproate-treated or saline-treated injured or uninjured mice
as they were all upward of 99%.
In the SGZ, there was a trend noted for increased new cell
density in valproate-treated ligation-uninjured mice ipsilaterally
(p = 0.063), while there was a signiﬁcant increase contralaterally
(p = 0.028; see Figure 4C). In ligation-injured animals, there
was no signiﬁcant difference in new cell density in SGZ between
valproate and saline-treatment ipsilaterally (p= 0.964) while there
was a trend noted for increased cell density in valproate-treated
animals contralaterally (p = 0.095; Figure 4C). In uninjured mice,
there was also an increase in the percent of cells labeled with BrdU
along the SGZ that also expressed NeuN among valproate-treated
animals compared to saline-treated, contralaterally (p = 0.041)
although the increase was not signiﬁcant ispilaterally (p = 0.125;
Figure 4D). In injured mice, there was no signiﬁcant difference
between the two treatments in the percent of cells co-labeled either
contralaterally or ipsilaterally (p = 0.533 and 0.850, respectively;
Figure 4D).
There were no signiﬁcant differences noted in densities of
new BrdU–NeuN co-labeled cells in the hilus after treatment
with valproate or saline in either ligation-injured or unin-
jured animals. In injured mice, contralateral mean count val-
proate = 0.33 ± 0.06 cells versus saline = 0.50 ± 0.12 cells,
p = 0.243; and ipsilateral mean count valproate = 0.28 ± 0.10
cells versus saline = 0.49 ± 0.13 cells, p = 0.232. In uninjured
mice, contralateralmean count valproate= 0.31± 0.07 cells versus
saline = 0.42 ± 0.15 cells, p = 0.533; and ipsilateral mean count
valproate = 0.54 ± 0.11 cells versus saline = 0.56 ± 0.11 cells,
p = 0.938. No signiﬁcant sex differences were noted in neurogenic
responses.
TRICHOSTATIN A TREATMENT
Seizure scores
In Protocol 1, seizure scores ranged from 0 to 75 (median = 0) in
the TSA-treated and 0 to 104 (median = 0) in the DMSO-treated
animals (N.S.). In Protocol 2, seizure scores ranged from 0 to 21
(median = 0) in the TSA-treated and 0 to 0 (median = 0) in the
DMSO-treated (N.S.). Seizures correlated with hemispheric brain
atrophy in both TSA- (r2 = 0.560, p = 0.016) and DMSO-treated
animals (r2 = 0.682, p = 0.007).
Treatment groups and associated mortality
The sample size of TSA- or DMSO-treated ligated mice in Protocol
1 was n = 19 TSA- and 16 DMSO-treated (see Table 1 for details).
Compared to DMSO (3/16 died), mortality associated with the
TSA-treatment (5/19 died) was not signiﬁcantly higher (Fisher’s
exact p = 0.700). The sample size for ligated mice in Protocol
2 was 16 TSA-treated and 10 DMSO-treated mice. Compared to
DMSO (1/10 died), mortality associated with the TSA-treatment
(1/16 died) was not signiﬁcantly higher (Fisher’s exact p = 1.000).
When themortality data from theﬁrst 42days of bothprotocols are
added together, the mortality in the TSA-treated group is still not
signiﬁcantly higher compared to DMSO-treated ligated animals
(Fisher’s exact p = 1.000).
Impact upon weight gain
Stroke injuredmice treatedwithTSAdid not exhibit alteredweight
gain compared to DMSO-treated injured mice in either females or
males (Figure 3B).
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FIGURE 4 | Brain atrophy and dentate gyrus neurogenesis after valproate
treatment in Protocol 2. (A) Severity of hemispheric and hippocampal
brain atrophy following P12 ligations quantiﬁed at P42 in ligation-injured
mice. (B) Average densities of BrdU+/NeuN+ within the GCL in both
ligation-uninjured (left panel) and ligation-injured (right panel) mice treated
with valproate or saline. (C) Average densities of BrdU+/NeuN+ cells along
the SGZ in both ligation-uninjured (left panel) and ligation-injured (right panel)
mice treated with valproate or saline. (D) Percent of BrdU-positive cells along
the SGZ that express NeuN in both ligation-uninjured (left panel) and ligation-
injured (right panel) mice treated with valproate or saline (*p < 0.05).
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Impact on brain atrophy
In Protocol 1 the stroke-injury related atrophies in the
DMSO-treated group was very similar to the TSA-treated group
of ligation-injured mice (34.9 ± 7.2 and 37.3 ± 7.5% hemispheric
atrophy, respectively, and 57.6± 8.3 and 59.6± 6.6%hippocampal
atrophy, respectively; p = 0.821 and 0.858, respectively). Simi-
larly at P42 (Protocol 2) there were no signiﬁcant differences in
brain atrophy (Figure 5A; DMSO = 20.2 ± 6.9% hemispheric
and 32.5 ± 8.6% hippocampal atrophy; TSA = 29.6 ± 3.3%
hemispheric and 49.5 ± 5.4% hippocampal atrophy; p = 0.190
and 0.118, respectively). No gender related differences within each
group were found to be signiﬁcant for severity of brain atrophy at
P42 or at P60.
Impact on neurogenesis
Protocol 1 treatment with TSA also demonstrated no
change in neurogenesis within treatment groups compared
to DMSO-treated controls in stroke-uninjured (mean den-
sity of BrdU labeled cells in contralateral GCL + SGZ in
TSA = 770 ± 109 cells/mm2 versus DMSO = 779 ± 69 cells/mm2,
p = 0.956; mean ipsilateral density in TSA = 719 ± 104 cells/mm2
versus DMSO = 676 ± 57 cells/mm2, p = 0.777) or
in the stroke-injured mice (mean contralateral density in
TSA = 642 ± 52 cells/mm2 versus DMSO = 542 ± 60, p = 0.240;
mean ipsilateral density in TSA = 495 ± 72 cells/mm2 versus
DMSO = 498 ± 55 cells/mm2, p = 0.974).
However, compared to vehicle-treated injured controls,
Protocol 2 treatment with TSA for 9 days before BrdU labeling,
resulted in increases in DG neurogenesis (determined as cell
density or as cell counts; density reported here) in animals
treated with TSA (2.5 mg/kg). One TSA-treated injured ani-
mal had excessively high density of DG BrdU–NeuN co-labeled
cells bilaterally (greater than four times the mean) and was
excluded from this analysis. In ligation-injured mice, new cell
density was signiﬁcantly higher with TSA-treatment in ipsilat-
eral GCL (p = 0.045), but the increase was not signiﬁcant
in contralateral GCL (p = 0.139; see Figure 5B). With TSA-
treatment in uninjured animals, new cell density was signiﬁcantly
increased in GCL in both contralateral and ipsilateral hemispheres
(p = 0.002 and 0.0003, respectively; Figure 5B). No differ-
ences were noted between percent of cells labeled with BrdU
within GCL that express NeuN when comparing TSA-treated
with DMSO-treated injured or uninjured mice as they were all
above 99%.
In ligation-injured mice, mean new cell density along the
SGZ was signiﬁcantly increased contralaterally in mice treated
with TSA (p = 0.045) although the increase was not signiﬁ-
cant ipsilaterally (p = 0.232; Figure 5C). In ligation-uninjured
mice, new cell density was signiﬁcantly elevated along the SGZ in
both hemispheres with TSA-treatment (contralateral, p = 0.007;
ipsilateral, p = 0.010; Figure 5C). Similarly to the effects of val-
proate, after treatment with TSA, there were higher percentages
of BrdU+ cells in SGZ that co-labeled with NeuN. In ligation-
uninjured mice, there was a signiﬁcant increase in contralateral
SGZ (p = 0.002), but only a trend for increase in ipsilateral
SGZ (p = 0.081; Figure 5D). In ligation-injured mice, there
was a trend for increased percent co-labeling in contralateral
SGZ (p = 0.054), but no signiﬁcant increase in ipsilateral SGZ
(p = 0.523).
No signiﬁcant differences were noted in counts of BrdU–NeuN
co-labeled cells in the hilus corresponding with TSA or DMSO
treatment in ligation-injured animals (contralateral mean count
TSA = 1.04 ± 0.21 cells versus DMSO = 1.30 ± 0.34 cells,
p = 0.524; and ipsilateral mean count TSA = 0.96 ± 0.25 cells
versus DMSO = 1.05 ± 0.29 cells, p = 0.827). In ligation-
uninjured animals, contralateral mean counts in mice treated with
TSA = 1.56 ± 0.16 versus DMSO = 0.92 ± 0.17, p = 0.027;
and ipsilateral mean counts in TSA = 1.96 ± 0.59 versus
DMSO = 0.96 ± 0.23, p = 0.172.
Poisson regression of neurogenesis
Rostral to caudal analysis by section did not elucidate any differ-
ences in patterns of distribution of neurogenesis in either GCL
or SGZ in animals treated with valproate, TSA or their vehicles.
In uninjured animals treated with TSA versus DMSO, analysis by
section revealed a pattern of increased counts rostral to caudal in
contralateral hilus (p = 0.034) and a trend for the same in ipsilat-
eral hilus (p = 0.052). This pattern of counts in the hilus by section
was not seen in injured animals treated with TSA or DMSO, or any
animals treated with valproate or saline (see Figures 6 and 7).
Cognitive testing
Analysis of total distance traveled for the valproate group (i.e.,
injured mice given valproate, their injured saline-controls and
the shams) revealed only a main effect of day (F1,34 = 16.743,
p < 0.001; Figure 8A) due to an overall decrease in ambulation
from day 1 to day 2 (habituation). Analysis of the rearing data
for this group of animals also revealed a main effect of day
(F1,34 = 8.258, p = 0.007; Figure 8B). To evaluate within session
habituation, the total distance traveled during the entire 30-min
session was analyzed in 5-min blocks for each day. Analysis of the
valproate group revealed only a signiﬁcant main effect of block for
both sessions (F5,170 = 169.753, and F5,170 = 172.389, p < 0.001;
Figure 8C). Analysis of the data for the injured valproate -treated
group of mice did not reveal any signiﬁcant effects for the per-
cent alternation rate (see Figure 8D), percent right turns made,
or number of trials completed. The overall analysis of the novel
object preference task data for the valproate group of mice did
not reveal any signiﬁcant differences. However, given the appar-
ent low preference score of the valproate ligation-injured mice
(≈0.5, indicating no preference), we constructed a simple con-
trast to compare the preference ratio between the valproate and
sham mice, and a signiﬁcant P-value was obtained (t25 = 2.132,
p = 0.043; Figure 8E) suggesting impaired recognition mem-
ory in the valproate-treated ligation-injured mice. The failure to
obtain a signiﬁcant effect with the omnibus ANOVA likely reﬂects
insufﬁcient power to detect a difference.
Similar to the valproate group, analysis of the total distance
traveled by the TSA group (i.e., injured mice given TSA, their
injured DMSO-controls, and shams) also yielded a signiﬁcant
main effect of day (F1,34 = 7.148, p = 0.011; Figure 9A). How-
ever, in contrast to the valproate group, analysis of the rearing data
for the TSA group yielded a signiﬁcant main effect of Condition
(F2,34 = 7.190, p = 0.002) in addition to the main effect of day
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FIGURE 5 | Brain atrophy and dentate gyrus neurogenesis afterTSA
treatment in Protocol 2. (A) Severity of infarct injury following P12 ligations
quantiﬁed at P42 (14 days following cessation of treatment with TSA or
DMSO-vehicle at P28) in ligation-injured mice. (B) Average densities of
BrdU+/NeuN+ within the granule cell layer (GCL) in both ligation-uninjured
(left panel) and ligation-injured (right panel) mice treated with TSA or DMSO.
(C) Average densities of BrdU+/NeuN+ cells along the subgranular zone
(SGZ) in both ligation-uninjured (left panel) and ligation-injured (right panel)
mice treated with TSA or DMSO. (D) Percent of BrdU-positive cells along
the SGZ that express NeuN in both ligation-uninjured (left panel) and
ligation-injured (right panel) mice treated with TSA or DMSO (*p < 0.05,
**p < 0.01, ***p < 0.001).
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FIGURE 6 | Aerial analysis (rostral to caudal) of BrdU–NeuN
density (A–D) or counts (E,F) in mice treated with valproate
or saline in Protocol 2. (A,B) Average densities of BrdU+/NeuN+
within the contralateral (A) and ipsilateral (B) GCL in both ligation-
uninjured (left panel) and ligation-injured (right panel) mice treated
with valproate or saline. (C,D) Average densities of BrdU+/NeuN+
cells along the contralateral (C) and ipsilateral (D) SGZ in both ligation-
uninjured (left panel) and ligation-injured (right panel) mice treated with
valproate or saline. (E,F) Average counts of BrdU+/NeuN+ cells in the
contralateral (E) and ipsilateral (F) hilus in both ligation-uninjured (left panel)
and ligation-injured (right panel) mice treated with valproate or saline
(*p < 0.05, **p < 0.01).
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FIGURE 7 | Aerial analysis (rostral to caudal) of BrdU–NeuN
density (A–D) or counts (E,F) in mice treated withTSA or DMSO
in Protocol 2. (A,B) Average densities of BrdU+/NeuN+ within the
contralateral (A) and ipsilateral (B) GCL in both ligation-uninjured
(left panel) and ligation-injured (right panel) mice treated with TSA or
DMSO. (C,D) Average densities of BrdU+/NeuN+ cells along
the contralateral (C) and ipsilateral (D) SGZ in both ligation-uninjured (left
panel) and ligation-injured (right panel) mice treated with TSA or DMSO.
(E,F) Average counts of BrdU+/NeuN+ cells in the contralateral (E) and
ipsilateral (F) hilus in both ligation-uninjured (left panel) and ligation-injured
(right panel) mice treated with TSA or DMSO (*p < 0.05, **p < 0.01,
***p < 0.001).
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FIGURE 8 | Results of behavioral studies in valproate- and
saline-treated injured mice compared to sham controls in
Protocol 1. (A–C) Open ﬁeld studies demonstrated no signiﬁcant
differences in distance traveled, rearing behavior or habituation.
(D)T-maze alternation test demonstrated no signiﬁcant differences
between the groups. (E) Ligation-injured mice receiving valproate
performed less well on novel object testing compared to sham controls
(*p < 0.05).
(F1,34 = 12.012, p = 0.001; Figure 9B). The effect of Condition
is due to the shams rearing more than either the TSA- or DMSO-
treated mice; there were no differences between the TSA- and
DMSO-treated on this measure. The main effect of day was again
due to habituation across the sessions. Analysis of within session
habituation in the TSA group of mice also yielded only signiﬁ-
cant effects for Block for both the day 1 session (F5,170 = 160.462,
p < 0.001) and the day 2 session (F5,170 = 157.558, p < 0.001).
These results illustrate that all mice habituated within each session
on both days (see Figure 9C). There were no other main effects or
interactions for the TSA group of mice.
Analysis of the data for the injured TSA group of mice did not
yield any signiﬁcant effects for the alternation rate (see Figure 9D),
percent right turns made, or number of trials completed. There
were also no effects for the number of trials completed by each
group (TSA or controls). In addition, analysis did not reveal a
signiﬁcant difference in the preference ratio for novel objects (see
Figure 9E).
Unilateral strokes are known to elicit circling movements
in rodents (Kadam et al., 2010); this comorbidity worsens in
frequency and severity over time and is associated with the devel-
opment of hyperactivity seen in a subset of the animals. We
therefore measured the clockwise and counter-clockwise rotations
of all (non-hyperactive) mice during the open ﬁeld sessions. How-
ever, the only signiﬁcant differences we observed were main effects
in clockwise rotations from day 1 to day 2 (TSA: F1,34 = 5.084,
p = 0.031; valproate: F1,35 = 6.875, p =0.013) and counterclock-
wise rotations from day 1 to day 2 (TSA: F1,34 = 7.799, p = 0.009;
valproate: F1,35 = 6.443, p = 0.016). These differences reﬂect the
decrease in activity from day 1 to day 2 seen across all subjects
and noted in the open ﬁeld section above. There were no other
differences either across or within each of the 2 days (in either
the valproate- or the TSA-treated animals). This difference, com-
pared to our prior study, may be due to the animals being studied
at earlier time-points after the stroke injury, and the removal of
hyperactive animals from the analysis.
Valproate serum analysis
Twenty mouse pups were administered valproate starting at P16,
and three died before blood collection at P26. The mean afternoon
peak level (n = 5) of valproate in serum was 241.9 ± 18.1 μg/ml.
Therewere four samples for a corresponding trough level, of which
three fell below levels of detection and one was 2.2 μg/ml. The
mean peak level of valproate in serum after the morning dose
(n = 4) was 264.0 ± 20.6 μg/ml while the mean trough level
before the next dose (n = 4, one of which was below levels of
detection) was 2.0 ± 0.3 μg/ml, resulting in a half-life of less
than 1.0 h.
DISCUSSION
In the present study, we determined whether administration of
valproate, an anticonvulsant with multiple mechanisms of action
including HDAC inhibition, and its positive control TSA, a potent
broad HDAC inhibitor with no known anti-convulsant action,
when given for almost 2 weeks during early life following a
stroke, inﬂuences neurogenesis in the dorsal hippocampus of the
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FIGURE 9 | Results of behavioral studies inTSA- and DMSO-
treated injured mice compared to sham controls in Protocol 1.
(A–C) Open ﬁeld studies demonstrated no signiﬁcant differences
in distance traveled and habituation, however the injured animals
in both treatment groups reared less than the shams. (D)T-maze
alternation test demonstrated no signiﬁcant differences between
the groups. (E) Novel object testing also demonstrated no signiﬁcant
differences (*p < 0.001).
maturing brain. After neonatal stroke, mice were administered the
drugs twice daily from P16 to P28, but not during the immediate
post-injury period, in order to avoid producing a secondary effect
upon neurogenesis resulting primarily from an acute neuropro-
tective effect of the drug. The data presented demonstrate that (1)
chronic HDAC treatment during this regenerative period did not
modify the severity of stroke-related brain atrophy assessed at P60
or at P42, (2) BrdU labeling at 8–10 days post-stroke (4–6 days
after either valproate or TSA initiation) showed no signiﬁcant
changes in DG neurogenesis compared to vehicle controls, (3)
BrdU labeling at 12–14 days after stroke (7–9 days after either
valproate or TSA initiation) revealed a signiﬁcant increase in DG
neurogenesis producedbyTSAor valproate both in the injured and
uninjured animals compared to the vehicle controls in both sexes
and (4) valproate, but not TSA, was associated with an increase
in mortality, impaired animal weight gain, and mild cognitive
impairment.
Initially, we labeled with BrdU at P20–22 and waited approx-
imately 4 weeks for the new granule cells to mature and be
incorporated into circuitswithin theGCL.However, nodifferences
were noted between drug and saline treatments. We had several
hypotheses for why this may have been the case and designed
Protocol 2 with these hypotheses in mind. The immature brain
has a high level of neurogenesis compared with the more mature
brain, which may reﬂect the highly plastic nature of the imma-
ture brain and its ability to learn (Kuhn et al., 1996). However
it may also mean that this high level of plasticity and neurogene-
sis cannot be up-regulated any further by epigeneticmanipulation;
this situation may in part explain the lack of statistically signiﬁcant
increased neurogenesis noted in Protocol 1. As the animal ages and
the neurogenesis falls below neonatal levels, however, induction of
neurogenesis may become amenable by drugs that up-regulate the
gene groups controlling neural development. In addition, the ani-
mal handling during behavioral testing in Protocol 1 likely also
increased the post-stroke neurogenesis in all groups, thus making
it more difﬁcult to demonstrate a statistically signiﬁcant increase
in neurogenesis due to the HDAC inhibitors in Protocol 1.
On the other hand, it may also be possible that the 4–6 days
of HDAC inhibition prior to administration of BrdU is insufﬁ-
cient to induce epigenetic changes that underlie SGZ neurogenesis
in an immature brain; however, previous studies have shown up-
regulation of neurogenesis with 3 day exposure of TSA in adult rats
in a stroke model (Kim et al., 2009). Another possibility is that the
evolving secondary inﬂammatory responses to the stroke injury
(Faustino et al., 2011) may temporarily suppress HDAC activity
producing a lack of response toHDAC inhibitors. The difference in
neurogenic response between uninjured TSA-treated and injured
TSA-treated mice supports this point, however a lack of a response
in the uninjured animals in protocol 1, alongwith robust responses
from uninjured animals in Protocol 2 argues against this being the
sole factor at play. Finally, it is also possible that the increased
neurogenesis noted with the BrdU administered in Protocol 2
(with survival to P42), but not when administered in Protocol 1
(with survival to P60), suggests that the HDAC inhibitors in these
immature animals primarily increased SGZ proliferation and/or
short-term survival and differentiation, rather than long-term
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survival, maturation, migration, and integration of the newborn
SGZ granule cells. The small but signiﬁcant increase in percent
BrdU–NeuN co-labeling noted in the SGZ with HDAC inhibitor
treatment supports this hypothesis. This result could represent
an important alteration in the normal migration of these matur-
ing neurons, or a reduction in normal loss of new-born neurons
which do not properly migrate into the GCL. Future studies are
needed determine which of these factors contribute to the dif-
ferent neurogenic responses seen when BrdU was administered
under the two different protocols. Also, additional study is needed
to determine the fate of the non-colabeled cells within the SGZ.
Increased normal SGZ neurogenesis would be expected to reduce
the risk of post-stroke epilepsy and cognitive impairments; how-
ever additional abnormal post-stroke and post-ischemic seizure
neurogenesis could further contribute to abnormal hippocampal
circuit formation and increase the risk of post-stroke morbid-
ity (Jessberger et al., 2007). Importantly, treatment with TSA or
valproate did not result in a change in newborn BrdU–NeuN co-
labeled hilar or GCL neurons; alterations which would suggest
aberrant migration of newborn neurons.
There was greater variability noted in densities of BrdU–NeuN
cells in valproate-treatedmice as compared to those inTSA-treated
mice. The reason for this higher variability in valproate is not clear
but may relate to non-CNS systemic effects of valproate on the
liver or other mechanisms related to its toxicity and the effect of
this on neurogenesis. It may also be noted that the neurogenesis
seen with the saline and DMSO controls was different. DMSO
may have some effect itself on neurogenesis, which is different
from that noted with saline. There has been reported neurotoxic-
ity associated with DMSO (Hanslick et al., 2009) that theoretically
could affect neurogenesis differently as compared to saline. As the
two drugs, valproate and TSA were dissolved in different solu-
tions (saline and DMSO, respectively), it was important to have
the proper controls for each of the drugs. The effects that these
two vehicles have on neurogenesis could be different and there-
fore, it is vital to separate the effect of drug from that of vehicle.
In the uninjured animals the effect of drugs upon the GCL was
greater than their effect upon the SGZ; likely this is because at this
timepoint many of the BrdU labeled cells have moved out of the
SGZ and begun to differentiate. Because the effect of the drugs
upon the SGZ was smaller, and given the variability in the results,
it is likely that signiﬁcance was not reached bilaterally in the SGZ
measurement due to the number of animals used.
Trichostatin A did not produce any detected behavioral detri-
ment in open-ﬁeld, novel object preference or spontaneous
alternation testing. Testing was done at P38–42; by this time
newborn granule cells labeled at P20–22, or at P24–P26, have dif-
ferentiated and migrated but are not expected to be fully matured
and integrated (Kee et al., 2007). Recently it has been reported that
4–6 weeks is the time period required for adult neurogenesis to
impact the novel object task (Denny et al., 2012). Full assessment
of effects of increased neurogenesis, observed after BrdU label-
ing P24–26 and due to HDAC inhibition, may require additional
testing of behavioral outcomes at about 2 months of age.
Valproate on the other hand may have contributed to mild
cognitive impairments on novel object testing, although whether
by HDAC inhibition or by another mechanism will require
further study. Visual-spatial impairments in adult rats have
been previously reported with prior chronic valproate-treatment
(300 mg/kg twice a day for 10 days) and were associated with
decreased SGZ proliferation (differentiation into neurons was not
assessed) and decreased hippocampal BDNF and Notch 1 expres-
sion (Umka et al., 2010). In another study, however, no impact
on SGZ proliferation, differentiation or survival was noted when
250 mg/kg valproate was administered once daily from P7 to P34
in rats, and BrdU was administered at P34 after the drug was dis-
continued (Chen et al., 2009). For neurogenesis studies, the age of
the animal, dose of the drug, and time-point at which the BrdU
is administered relative to the timing of drug or insult and when
the brain is inspected are all key determinants to the results and
produce challenges in comparing studies and interpreting results.
Fleiss et al. reported sex-dependent effects in the neonatal hypoxic-
ischemic-lipopolysaccharide (HI-LPS) model of brain injury. We
did not note sex-related differences; this difference likely relates to
the older age at which the neurogenesis was assessed in our study
(Fleiss et al., 2012).
Interpretation of the cognitive impairments associated with
valproate administration is further complicated by the associated
toxicity, as evidenced by the increased mortality and impaired
weight gain. Toxicity with valproate in rodents has been previ-
ously described. Valproate administered to rats, over a range of
ages starting at P10 and over a range of doses (which includes
the dose we administered) produced a drop in platelets, reduced
weight gain, and an increased urine creatinine concentration
(Espandiari et al., 2008). While TSA is a selective HDAC inhibitor,
valproate has multiple mechanisms of action including gamma-
aminobutyric acid (GABA) enhancement, N-methyl-D-aspartate
(NMDA) receptor modulation, and sodium channel blockade
(Monti et al., 2009). It is likely that the other mechanisms of action
account for the negative effects of valproate, perhaps in combi-
nation with HDAC inhibition. On the other hand, it has been
reported that HDAC6 inhibition can be protective in the setting of
oxidative stress (Kalin et al., 2012); TSA inhibits HDAC6, but val-
proate does not. Furthermore, valproate-treatment is associated
with increased HDAC2 degradation not seen with TSA-treatment
(Kramer et al., 2003). Therefore, it is possible that the differences
in HDAC selectivity account for some part of the noted valproate
toxicity. It is possible that a lower dose of valproate would have
produced the same effect on neurogenesis without the negative
effects upon mortality, weight gain and cognitive function; how-
ever the measured serum levels suggested that the dose being given
was not producing sustained therapeutic (anti-convulsant) levels.
The dose of valproate we chose is reported in the literature to
have anticonvulsant and neuroprotective effects, both acutely and
chronically (Iyer et al., 1995; Kabakus et al., 2005; Brandt et al.,
2006) and peak levels were reasonable and therapeutic based on
other rodent studies. However the pharmacokinetic serum levels
reported here suggest that, at least in normal juvenile mice chron-
ically administered valproate 200 mg/kg twice daily, the half-life
of valproate by P26 is very short and therapeutic drug levels are
not being maintained. We previously documented a half-life of
4.5 h with a single dose of 200 mg/kg of valproate in P19 CD1
mice (Markowitz et al., 2010). These data suggest that the half-life
of valproate decreases with age between P19 and P26, or that
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the chronic dosing up-regulates the metabolism of the drug. The
mortality associated with the 200 mg/kg twice-a-day dose prevents
increasing the dose further to obtain more consistent blood levels,
and the immature mice are too small to have a continuous pump
inserted. Therefore, it is not currently possible to obtain sustained
therapeutic levels of valproate in these animals.
In conclusion, the impact of HDAC inhibitors uponpost-stroke
neurogenesis is likely to depend on age, duration of treatment
before and after BrdU labeling, and timing of both treatment
and assessment after the ischemic brain injury. Future studies will
need to determine the extent of histone deacetylation and mecha-
nism(s) producing the increased post-stroke neurogenesis, as well
as the long-term functional impact of HDAC inhibitor-enhanced
neurogenesis. Differences in HDAC selectivity of function could
contribute to differences in the other systemic and cognitive effects
of valproate compared to TSA and deserve further study. Increas-
ing post-stroke neurogenesis after neonatal stroke is theoretically
one approach to enhancing cognitive recovery. With this goal in
mind, the data presented here suggests that HDAC inhibition may
be one strategy for obtaining increased post-stroke neurogenesis.
However, many questions and potential obstacles remain to be
addressed before pharmacologic treatment with a selective HDAC
inhibitor can be actively promoted for the treatment of neonatal
stroke. A stronger link between the increased neurogenesis and
improved functional outcome in neonatal ischemia models after
treatment with histone deactylase inhibitors needs to be pursued
with future studies. Concerns exist as to the impact of TSA upon
normal brain development and it may be that a more selective
histone deactylase inhibitor would ultimately be a better choice
should studies with HDAC inhibitors ever come to clinical trial.
Finally, epilepsy after neonatal stroke in babies is a concern and
further studies are needed to determine whether HDAC inhibitors
impact the risk of developing epilepsy after neonatal stroke and, if
so, how.
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